Enantiomeric Analogues of SCH 23390 as New Probes for Behavioral Interactions between D1 and D2 Dopaminergic Function

  • John L. Waddington
  • Anthony G. Molloy
  • Kathy M. O’Boyle
  • Marcellina Mashurano
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 204)


The recent identification of the first selective D1 dopamine (DA) receptor antagonist, the 1-phenyl-1H-3-benzazepine derivative SCH 23390 (Iorio et al., 1983; Hyttel, 1983; Cross, et al., 1983; O’Boyle and Waddington, 1984a), was an event eagerly awaited as the final piece in a psychopharma-cological jigsaw that had for some time remained incomplete. The now widely accepted designation of D1 and D2 subtypes of DA receptor (Kebabian and Calne, 1979; Seeman, 1980; Leff and Creese, 1983; Waddington, et al., 1986) arose in the absence of selective D1 antagonists. Therefore, such a drug was clearly required to substantiate any functional distinctions between these subtypes, in the classical manner of previous schemes for heterogeneity in non-DAergic receptor populations.


Dopamine Receptor Dopamine Agonist Stereotyped Behavior Dopamine Antagonist Agonist Apomorphine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arnt, J., 1985, Hyperactivity induced by stimulation of separate dopamine D1 and D2 receptors in rats with bilateral 6-OHDA lesions, Life Sci., 37:717.PubMedCrossRefGoogle Scholar
  2. Arnt, J. and Hyttel, J., 1984, Differential inhibition by dopamine D1 and D2 antagonists of circling behavior induced by dopamine agonists in rats with unilateral 6-hydroxydopamine lesions, Eur. J. Pharmacol., 102:349.PubMedCrossRefGoogle Scholar
  3. Billard, W., Ruperto, V., Crosby, G., Iorio, L.C. and Barnett, A., 1984, Characterization of the binding of 3H-SCH-23390, a selective D1 receptor antagonist ligand in rat striatum, Life Sci., 35:1885.PubMedCrossRefGoogle Scholar
  4. Breese, G.R. and Mueller, R.A., 1985, SCH 23390 antagonism of a D2 dopamine agonist depends upon catecholaminergic mechanisms, Eur. J. Pharmacol., 113:109.PubMedCrossRefGoogle Scholar
  5. Christensen, A.V., Arnt, J., Hyttel J., Larsen, J.J. and Svendsen, O., 1984, Pharmacological effects of a specific dopamine antagonist SCH 23390 in comparison with neuroleptics, Life Sci., 32:1529.CrossRefGoogle Scholar
  6. Creese, I., Sibley, D.R., Hamblin, M.W. and Leff, S.E., 1983, The classification of dopamine receptors: Relationship to radioligand binding, Ann. Rev. Neurosci., 6:43.PubMedCrossRefGoogle Scholar
  7. Cross, A.J., Mashal, R.D., Johnson, J.A. and Owen, F., 1983, Preferential inhibition of ligand binding to calf striatal dopamine D1 receptors by SCH23390, Neuropharmacol., 22:1327.CrossRefGoogle Scholar
  8. Cross, A.J., Hewitt, L., Slater, P. and Waddington, J.L., Interactions of benzazepine derivatives with rat brain serotonin receptors. In preparation.Google Scholar
  9. Dandridge, P.A., Kaiser C., Bremer, M., Gaitanopoulos, D., Davis, L.D., Webb, R.G., Foley, J.J. and Sarau, H.M., 1984, Synthesis, resolution, absolute stereochemistry, and enantioselectivity of 3’,4’-dihydroxynomifensine, J. Med. Chem. 27:28.PubMedCrossRefGoogle Scholar
  10. Gerson, S.C. and Baldessarini, R. J., 1980, Motor effects of serotonin in the central nervous system, Life Sci. 27:1435.PubMedCrossRefGoogle Scholar
  11. Hyttel, J., 1983, SCH 23390: The first selective dopamine D1 antagonist, Eur. J. Pharmacol. 91:153.PubMedCrossRefGoogle Scholar
  12. Iorio, L.C., Barnett, A., Leitz, F.H., Houser, V.P. and Korduba, C.A., 1983, SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems, J. Pharmacol. Exp. Ther. 226:462.PubMedGoogle Scholar
  13. Isaacson, R.L., Hannigan, J.H., Brakkee, J.H., and Gispen, W.H., 1983, The time course of excessive grooming after neuropeptide administration, Brain Res. Bull. 11:289.PubMedCrossRefGoogle Scholar
  14. Itoh, Y., Beaulieu, M. and Kebabian, J.W., The chemical basis for the blockade of the D-1 dopamine receptor by SCH23390, 1984, Eur. J. Pharmacol. 100:119.PubMedCrossRefGoogle Scholar
  15. Jenner, P. and Marsden, C.D., 1979, The substituted benzamides: A novel class of dopamine antagonists, Life Sci., 25:479.PubMedCrossRefGoogle Scholar
  16. Jolies, J., Rompa-Barendregt, J. and Gispen, W.H., 1979, Novelty and grooming behavior in the rat, Behav. Neural Biol., 25:563.CrossRefGoogle Scholar
  17. Kaiser, C., Dandridge, P.A., Garvey, E., Hahn, R.A., Sarau, H.M., Setler, P.E., Bass, L.S. and Clardy, J., 1982, Absolute stereochemistry and dopaminergic activity of enantiomers of 2,3,4,5-tetrahydro-7, 8-dihydroxy-1-phenyl-1H-3-benzazepine, J. Med. Chem., 25:687.CrossRefGoogle Scholar
  18. Kebabian, J.W. and Calne, D.B., 1979, Multiple receptors for dopamine, Nature 277:93.PubMedCrossRefGoogle Scholar
  19. Laduron, P., 1983, Dopamine sensitive adenylate cyclase as a receptor site, in: Dopamine Receptors, C Kaiser, and J.W. Kebabian, eds., American Chemical Society, Washington.Google Scholar
  20. Leff, S. and Creese, I., 1983, Dopamine receptors re-explained, Trends Pharmacol. Sci. 4:463.CrossRefGoogle Scholar
  21. Mailman, R.B., Schulz, D.W., Lewis, M.H., Staples, L., Rollema, H. and Dehaven, D.L., 1984, SCH 23390: A selective D1 dopamine antagonist with potent D2 behavioral actions, Eur. J. Pharmacol. 101:159.PubMedCrossRefGoogle Scholar
  22. Mailman, R.B., Schulz, D.W. and Kilts, C.D., 1985, D1-like dopamine receptors: Recognition sites with selectivity for SCH 23390 that are not linked to adenylate cyclase, Soc. Neurosci. Abstr. 11:313.Google Scholar
  23. Molloy, A.G. and Waddington, J.L., 1984, Dopaminergic behavior stereospecifically promoted by the D1 agonist R-SK&F 38393 and selectively blocked by the D1 antagonist SCH 23390, Psychopharmacol. 82:409.CrossRefGoogle Scholar
  24. Molloy, A.G. and Waddington, J.L., 1985a, Sniffing, rearing and locomotor responses to the D1 dopamine agonist R-SK&F 38393 and to apomorphine: Differential interactions with the selective D1 and D2 antagonists SCH 23390 and metoclopramide, Eur. J. Pharmacol. 108:305.PubMedCrossRefGoogle Scholar
  25. Molloy, A.G. and Waddington, J.L., 1985b, The enantiomers of SK&F 83566, a new selective D1 dopamine antagonist, stereospecifically block stereotyped behavior induced by apormorphine and by the selective D2 agonist RU 24213, Eur. J. Pharmacol. 116:183.PubMedCrossRefGoogle Scholar
  26. Molloy, A.G., O’Boyle, J.M., Pugh, M.T. and Waddington, J.L., Locomotor behaviors in response to new selective D1 and D2 dopamine receptor agonists, and the influence of selective antagonists (In press), Pharmacol. Biochem. Behav.Google Scholar
  27. Morelli, M. and DiChiara, G., 1985, Catalepsy induced by SCH 23390 in rats, Eur. J. Pharmacol., 117:179.PubMedCrossRefGoogle Scholar
  28. O’Boyle, K.M. and Waddington, J.L., 1984a, Selective and stereospecific interactions of R-SK&F 38393 with 3H-piflutixol but not 3H-spiperone binding to striatal D1 and D2 dopamine receptors: comparisons with SCH 23390, Eur. J. Pharmacol. 90:433.CrossRefGoogle Scholar
  29. O’Boyle, K.M. and Waddington, J.L., 1984b, Identification of the enantiomers of SK&f 83566 as specific and stereoselective antagonists at the striatal D1 dopamine receptor: Comparisons with the D2 enantioselectivity of Ro 22–1319., Eur. J. Pharmacol. 106:219.PubMedCrossRefGoogle Scholar
  30. O’Boyle, K.M. and Waddington, J.L., 1985a, Binding of 3H-SCH 23390, a selective D1 dopamine receptor antagonist in human brain, Brit. J. Pharmacol. 86:435P.Google Scholar
  31. O’Boyle, K.M. and Waddington, J.L., 1985b, Structural determinants of selective affinity for brain D1 dopamine receptors within a series of l-phenyl-1H-3-benzazepine analogues of SK&F 38393 and SCH 23390, Eur. J. Pharmacol. 115:291.PubMedCrossRefGoogle Scholar
  32. O’Boyle, K.M., Molloy, A.G. and Waddington, J.L., Benzazepine derivatives: Nature of the selective and stereospecific interactions of SK&F 38393 and SCH 23390 with brain D1 receptors in: “Dopaminergic Systems and their Regulation”, G.N. Woodruff, ed., (In Press) Macmillan Press, London.Google Scholar
  33. Pugh, M.T., O’Boyle, K.M., Molloy, A.G. and Waddington, J.L., 1985, Effects of the putative D1 antagonist SCH 23390 on stereotyped behavior induced by the D2 agonist RU 24213, Psychopharmacol. 87:308.CrossRefGoogle Scholar
  34. Robertson, A. and MacDonald, C., 1985, Opposite effects of sulpiride and metoclopramide on amphetamine-induced stereotypy, Eur. J. Pharmacol. 109:81.PubMedCrossRefGoogle Scholar
  35. Schulz, D.W., Stanford, E.J. and Mailman, R.B., Subcellular localization hte SCh23390 receptor: Dissociation from dopamine-stimulated adenylate cyclase, 1985, Soc. Neurosci. Abstr. 11:888.Google Scholar
  36. Seeman, P., 1980, Brain Dopamine receptors, Pharmacol. Rev. 32:229.PubMedGoogle Scholar
  37. Setler, P.E., Sarau, H.M., Zirkle, C.L. and Saunders, H.L, 1978, The central effects of a novel dopamine agonist, Eur. J. Pharmacol. 50:419.PubMedCrossRefGoogle Scholar
  38. Tricklebank, M.D., Forler, C., Middlemiss, D.N. and Fozard, J.R., 1985, Sub-types of the 5-HT receptor mediating the behavioral responses to 5-methoxy-N, N-dimethyltryptamine in the rat, Eur. J. Pharmacol., 117:15.PubMedCrossRefGoogle Scholar
  39. Waddington, J.L., 1985, Structural brain pathology and clinical features in schizophrenia: further clues on the neurobiology of psychosis, Trends Pharmacol. Sci. 8:374.Google Scholar
  40. Waddington, J.L., Cross, A.J., Gamble, S.J. and Bourne, R.C., 1982, Functional heterogeneity of multiple dopamine receptors during six months treatment with distinct classes of neuroleptic drugs., Adv. Biosci. 37:143.Google Scholar
  41. Waddington, J.L., Molloy, A.G., O’Boyle, K.M. and Pugh, M.T., Aspects of stereotyped and non-stereotyped behavior in relation to dopamine receptor subtypes. In “The Neurobiology of Behavioral Stereotypy”, S.J. Cooper, and C.T. Dourish, eds., Oxford University Press, London (in press).Google Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • John L. Waddington
    • 1
  • Anthony G. Molloy
    • 1
  • Kathy M. O’Boyle
    • 1
  • Marcellina Mashurano
    • 1
  1. 1.Department of Clinical PharmacologyRoyal College of Surgeons in IrelandDublin 2Ireland

Personalised recommendations